Pharmacology of zolimidine (2-(p-methylsulfonylphenyl)-imidazo (1,2-a) pyridine) a new non-anticholinergic gastroprotective agent. II) Protective activity against drug-induced experimental ulcers.
D000700:Analgesics / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001241:Aspirin; D006168:Guinea Pigs; D006632:Histamine; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006854:Hydrocortisone; D007093:Imidazoles / Q000627:therapeutic use*; D007213:Indomethacin; D010276:Parasympatholytics / Q000627:therapeutic use*; D010653:Phenylbutazone; D011725:Pyridines / Q000627:therapeutic use*; D051381:Rats; D013276:Stomach Ulcer / Q000139:chemically induced / Q000517:prevention & control*
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D006634:Histamine H1 Antagonists; D007093:Imidazoles; D010276:Parasympatholytics; D011725:Pyridines; D006632:Histamine; D010653:Phenylbutazone; D001241:Aspirin; D006854:Hydrocortisone; D007213:Indomethacin